Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

This study has been withdrawn prior to enrollment.
Advanced Diabetes Treatment Centers
Information provided by (Responsible Party):
Florida Atlantic University Identifier:
First received: October 3, 2007
Last updated: August 8, 2016
Last verified: August 2016
The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications on heart disease in diabetic patients. Patients are treated once a week with pulsatile intravenous insulin therapy mimicking normal insulin secretion. A diabetic cardiac disease quality of life questionnaire is completed prior to the start of the treatment and monthly thereafter with detailed analysis performed to measure progress and outcomes. A carotid ultrasound and echocardiogram are performed at baseline and every six months to monitor progress.

Condition Intervention Phase
Diabetes Mellitus, With Complications
Procedure: Intravenous Insulin on cardiac disease in diabetic pts
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Pulsatile Intravenous Insulin Therapy on Cardiac Disease in Patients With Diabetes

Resource links provided by NLM:

Further study details as provided by Florida Atlantic University:

Primary Outcome Measures:
  • Monitor and assess whether Pulsatile Intravenous Insulin Therapy can effect progression of cardiac disease in diabetic patients. Monitor results of Cardiac tests,carotid ultrasounds and echocardiograms,cardiac QOL, labs, meds to analyze progress. [ Time Frame: Testing is performed at baseline and every six months thereafter. ]

Enrollment: 0
Study Start Date: September 2007
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Diabetic patients will complete cardiac quality of life questionnaires at baseline and monthly thereafter to monitor and assess progress with complications resulting from their heart disease. Comparisons will be performed on carotid ultrasounds,echocardiograms and lab values performed at baseline and every six months and medication information collected at weekly Pulsatile Intravenous Insulin treatment sessions
Procedure: Intravenous Insulin on cardiac disease in diabetic pts
Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
Other Name: Humulin R, Novolog

  Show Detailed Description


Ages Eligible for Study:   21 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The researchers will include up to 400 pts between male and female between the ages of 21 and 85 diagnosed with diabetes mellitus and cardiac disease
  • Self reporting or diagnosed with significant complications resulting from diabetes
  • Taking oral agents and/or insulin for diabetic control
  • Under an Endocrinologist supervision for their diabetes management, Endocrinologist must assess and approve pt for participation in this study
  • Ability to swallow without difficulty
  • Ability to perform Respiratory Quotient requirements by breathing into a mask for 3 minutes at a time

Exclusion Criteria:

  • Lack of Intravenous access
  • Pregnancy
  • Alcohol abuse, drug addiction or the use of illegal drugs
  • Active liver disease
  • Active chemotherapy
  • Positive HIV
  • Inability to breathe into a respiratory quotient machine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00539435

United States, Florida
Betty Tuller PhD
Boca Raton, Florida, United States, 33431
Sponsors and Collaborators
Florida Atlantic University
Advanced Diabetes Treatment Centers
Principal Investigator: Betty Tuller, PhD Florida Atlantic University
  More Information

Responsible Party: Florida Atlantic University Identifier: NCT00539435     History of Changes
Other Study ID Numbers: H09-124
Study First Received: October 3, 2007
Last Updated: August 8, 2016

Keywords provided by Florida Atlantic University:
Diabetes Mellitus
Pulsatile Intravenous Insulin Therapy
Diabetic Cardiac Quality of Life
Cardiac Disease

Additional relevant MeSH terms:
Diabetes Mellitus
Heart Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cardiovascular Diseases
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on April 27, 2017